All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Alterity, Athenex, Aurigene Discovery, Beijing CC-Pharming, Bill & Melinda Gates Foundation, Bridge Biotherapeutics, China Grand, Clover, Curis, Ibio, Oncosec, Porton Pharma Solutions, Q Biomed, Recce.
HONG KONG – The recent coronavirus (2019-nCov) scare has led to a rush of demand for masks that could soon strain pharmaceuticals and med-tech companies alike. In Hong Kong, queues for surgical masks now snake around the block.
LONDON – As the death toll passed 1,000 and the number of confirmed cases reached 42,000, the World Health Organization on Feb. 11 convened 400 scientists at a global research and innovation forum to draw up an R&D blueprint for “pathogen X,” now officially named COVID-19.
BEIJING – Zhongshan-based Akeso Inc., which focuses on bispecific antibodies, is again seeking pre-revenue listing on the Hong Kong Stock Exchange (HKEX), after its first IPO attempt failed to go through in December. The move comes at a time when analysts believe the coronavirus outbreak is weighing on the city’s IPO market.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 7D Surgical, Autobio Diagnostics, Cepheid, China Grand Pharmaceutical and Healthcare Holdings, Co-Diagnostics, Elite Medical Technologies, Endonovo Therapeutics, Future Medical Equipment, Medtronic, Mobidiag, Oncosec Medical, Precisionmed, Probo Medical, Sirtex Medical, Seaspine Holdings, Sona Nanotech, Valeritas Holdings, Zealand Pharma.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angiogenex, Arbutus, Axim, Blue Water Vaccines, Clover, Gibson Oncology, Inmunebio, Intellia, Koutif, KSQ, Novozymes, Oncosec, Phio, Recce, Seurat, Synthetic Biologics, Zealand.
BEIJING – China’s partial shutdown caused by the 2019-nCoV coronavirus outbreak has sparked global fears of a disrupted supply chain of active pharmaceutical ingredients (API), as the country is a major exporter. Drugs that many depend on, such as ibuprofen and acarbose, could be affected.
RSS
